Neprilysin 2 catalyses the degradation of natriuretic peptides despite sacubitrilat Inhibition.

Selezneva, Elizaveta M et al.·Scientific reports·2025·Preliminary Evidencelaboratory study
RPEP-13503Laboratory studyPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
laboratory study
Evidence
Preliminary Evidence
Sample
N=Not applicable (laboratory study)
Participants
Recombinant enzymes and cardiovascular cell lines

What This Study Found

Neprilysin 2 (NEP2), a close relative of neprilysin, degrades natriuretic peptides ANP and BNP but is NOT blocked by sacubitrilat, the active form of the heart failure drug sacubitril. NEP2 is expressed in heart cells and blood vessel cells.

Key Numbers

NEP2 and NEP mRNA detected in cardiomyocytes and endothelial cells. NEP2 cleaved ANP and BNP. NEP2 was insensitive to sacubitrilat. NEP2 (but not NEP) cleaved proBNP to truncated form (amino acids 5-32).

How They Did This

RT-PCR for NEP and NEP2 expression in cardiovascular cells. In vitro cleavage assays using recombinant NEP and NEP2 soluble domains. Sandwich immunoassays with antibodies specific for proteolytic epitopes. Tested sacubitrilat inhibition.

Why This Research Matters

Heart failure patients take sacubitril to preserve natriuretic peptides. If NEP2 continues to break them down despite treatment, it could limit the drug's effectiveness. This reveals a potential therapeutic gap.

What This Study Doesn't Tell Us

In vitro study. NEP2 protein expression and activity in vivo not confirmed. Relevance to clinical heart failure outcomes is theoretical. Studied concentrations may not reflect physiological conditions.

Trust & Context

Original Title:
Neprilysin 2 catalyses the degradation of natriuretic peptides despite sacubitrilat Inhibition.
Published In:
Scientific reports, 15(1), 27401 (2025)
Database ID:
RPEP-13503

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Cite This Study

RPEP-13503·https://rethinkpeptides.com/research/RPEP-13503

APA

Selezneva, Elizaveta M; Feygina, Evgeniya E; Ageeva, Liudmila V; Rozov, Fedor N; Kopylova, Irina V; Altshuler, Evgeny P; Semenov, Alexander G. (2025). Neprilysin 2 catalyses the degradation of natriuretic peptides despite sacubitrilat Inhibition.. Scientific reports, 15(1), 27401. https://doi.org/10.1038/s41598-025-10166-z

MLA

Selezneva, Elizaveta M, et al. "Neprilysin 2 catalyses the degradation of natriuretic peptides despite sacubitrilat Inhibition.." Scientific reports, 2025. https://doi.org/10.1038/s41598-025-10166-z

RethinkPeptides

RethinkPeptides Research Database. "Neprilysin 2 catalyses the degradation of natriuretic peptid..." RPEP-13503. Retrieved from https://rethinkpeptides.com/research/selezneva-2025-neprilysin-2-catalyses-the

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.